- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT02251366
NVAMD Satellite Study
A Multi-Satellite Comparison of Standard-of-Care, Physician-Based Retinal Evaluation Versus Physician-Guided Diagnostic Evaluation in the Management of Neovascular Age-Related Macular Degeneration With Anti-Vascular Endothelial Growth Factor Therapy
Intravitreal delivery of anti-vascular endothelial growth factor (VEGF) drugs has revolutionized the management of neovascular age-related macular degeneration (NVAMD). However, the requirement for near monthly administration of therapy coupled with the growing number of patients needing treatment has become a universal challenge in efficient delivery of care for retina physicians. While many retina practices have both increased the size of their staffs to accommodate the growing patient population and increased efficiency with the aid of digital photography, patient encounter times in clinic continue to increase, often spanning 2-4 hours. While maintaining the highest level of patient care, a streamlined alternative in the evaluation of patients with NVAMD to determine whether intravitreal therapy with an anti-VEGF agent is indicated at a particular office visit would be desirable.
This multi-satellite, prospective, randomized pilot study will compare standard-of-care, physician- based retinal evaluation, defined as retinal examination by a physician and standard imaging with optical coherence tomography (OCT) and optional fluorescein angiography (FA), versus physician-guided diagnostic evaluation, defined as standard imaging with OCT and optional FA without retinal examination by a physician in the management of NVAMD with anti-VEGF therapy. Outcomes for this study are aimed primarily at demonstrating that the physician-guided diagnostic approach to managing patients with NVAMD is not inferior to the physician-based retinal evaluation based on measures such as a change from baseline in visual acuity and in central subfield thickness (CSF) on OCT. Other outcomes to be assessed in this study are length of visit times, numbers of intravitreal injections of anti-VEGF agents administered, numbers of diagnostic tests performed to determine whether treatment should be given at each visit, and frequency of retinal examinations performed for each participating patient in each cohort. Perceptions of quality of vision and patient satisfaction will be captured by interviews with patients following each clinic visit; clinical impressions of physicians will be captured by a brief physician survey. Finally, the feasibility of recruiting patients, as measured by how many eligible patients are seen at each Wilmer satellite, how many patients agree to be randomized, how many patients follow-up, and the attrition rates at the 4 and 8-month outcome visits will be assessed.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Faktisk)
Fas
- Inte tillämpbar
Kontakter och platser
Studieorter
-
-
Maryland
-
Bel Air, Maryland, Förenta staterna, 21014
- Wilmer Eye Institute
-
Bethesda, Maryland, Förenta staterna, 20814
- Wilmer Eye Institute
-
Columbia, Maryland, Förenta staterna, 21044
- Wilmer Eye Institute
-
Frederick, Maryland, Förenta staterna, 21702
- Wilmer Eye Institute
-
Lutherville, Maryland, Förenta staterna, 21093
- Wilmer Eye Institute
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion criteria:
- Established diagnosis of NVAMD in one or both eyes
- Received 2 or more intravitreal injections of anti-VEGF therapy from the retinal physician during the prior 6 months
- Need for more therapy on a near monthly basis is anticipated
- Usual corrected visual acuity (UCVA) of at least one eye must be 20/200 or better
- Must be physically able to cooperate with OCT and other diagnostic imaging procedures
- Must be able to give informed consent and be able to complete telephone surveys
Exclusion criteria:
- Systemic disease that can affect the peripheral retina (e.g., diabetes mellitus, sickle cell)
- History of symptomatic posterior vitreous detachment, retinal tear, or retinal detachment
- History of retinal surgery will not be enrolled.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Hälsovårdsforskning
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Enda
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Inget ingripande: SOC Examination Based Cohort
Participants in this arm will receive standard of care (SOC) retinal examinations at each study visit.
|
|
|
Aktiv komparator: Physician-Guided Diagnostic
Participants in this arm of the study will only receive the physical standard-of-care retinal examination at the 4-month and -month office visits, unless requested by the Physician-Investigator or study participant.
At each standard study visit, the physician will use diagnostic imaging to determine if the participant will receive the anti-VEGF injection.
|
NVAMD participants in the physician-guided diagnostic arm will have receive injections based on diagnostic imaging provided by optical coherence tomography and optional fluorescein angiography, those in this group will only receive retinal examinations at the 4- and 8-month clinic visits.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Change in visual acuity from baseline
Tidsram: up to two years
|
up to two years
|
|
Change in OCT CSF from baseline
Tidsram: up to two years
|
up to two years
|
Sekundära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
total encounter time for each arm
Tidsram: up to two years
|
up to two years
|
Andra resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Number of intravitreal anti-VEGF injections administered
Tidsram: up to two years
|
up to two years
|
|
number of diagnostic tests performed
Tidsram: up to two years
|
up to two years
|
|
number of retinal examinations performed
Tidsram: up to two years
|
up to two years
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Sharon Solomon, MD, Johns Hopkins University
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- NA_00088759
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .